KEROS THERAPEUTICS

keros-therapeutics-logo

Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with a high unmet medical need. Keros is a leader in understanding the role of the Transforming Growth Factor-Beta, or TGF-ß, family of proteins, which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone. Keros' lead ... protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros' lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from elevated levels of hepcidin, the key regulator of iron absorption and recycling, as well as for the treatment of fibrodysplasia ossificans progressiva. Keros' third product candidate, KER-012, is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension.

#SimilarOrganizations #People #Financial #Event #Website #More

KEROS THERAPEUTICS

Social Links:

Industry:
Biotechnology Health Care Pharmaceutical Therapeutics

Founded:
2015-01-01

Address:
Lexington, Massachusetts, United States

Country:
United States

Website Url:
http://www.kerostx.com

Total Employee:
11+

Status:
Active

Contact:
(617)513-8774

Total Funding:
90 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Content Delivery Network Euro Microsoft Exchange Online Amazon


Similar Organizations

aimmune-therapeutics-logo

Aimmune Therapeutics

Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.

baudax-bio-logo

Baudax Bio

Baudax Bio is a specialty pharmaceutical company focused on developing and commercializing innovative products for acute care settings.

clearside-biomedical-logo

Clearside Biomedical

Clearside BioMedical is an ophthalmic company that specializes in the research, development, and commercialization of therapeutic products.

crinetics-pharmaceuticals-logo

Crinetics Pharmaceuticals

Crinetics is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics.

edgewise-therapeutics-logo

Edgewise Therapeutics

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.

lixte-biotechnology-holdings-logo

Lixte Biotechnology Holdings

Lixte Biotechnology Holdings, a clinical-stage pharmaceutical company, focuses on discovering drugs for more effective cancer treatments.

os-therapies-logo

OS Therapies

OS Therapies is a therapeutics company focused on the identification, development, and commercialization of treatments for Osteosarcoma.

provention-bio-logo

Provention Bio

Provention Bio is a clinical stage biopharmaceutical dedicated to sourcing, developing and commercializing novel therapeutics.

rarecells-logo

Rarecells

Rarecells Inc. is a healthcare company focused on the development and commercialization of non-invasive Early Cancer Detection tests.

zymenex-logo

Zymenex

Zymenex is a Scandinavian biopharmaceutical company focused on the development and commercialization of novel enzyme replacement therapies


Current Advisors List

zafrira-avnur_image

Zafrira Avnur Board of Directors. @ Keros Therapeutics
Board_member

not_available_image

Ran Nussbaum Chairman of the Board of Directors @ Keros Therapeutics
Board_member

mary-ann-gray_image

Mary Ann Gray Board Member @ Keros Therapeutics
Board_member

Current Employees Featured

jasbir-seehra_image

Jasbir Seehra
Jasbir Seehra CEO @ Keros Therapeutics
CEO
2015-12-01

christopher-rovaldi_image

Christopher Rovaldi
Christopher Rovaldi COO @ Keros Therapeutics
COO
2022-01-01

annita-tanini_image

Annita Tanini
Annita Tanini Vice President of Finance, Controller @ Keros Therapeutics
Vice President of Finance, Controller
2019-05-01

Founder


jasbir-seehra_image

Jasbir Seehra

Stock Details


Company's stock symbol is NASDAQ:KROS

Investors List

orbimed-advisors_image

OrbiMed

OrbiMed investment in Series C - Keros Therapeutics

venrock_image

Venrock

Venrock investment in Series C - Keros Therapeutics

medison-pharma_image

Medison Pharma

Medison Pharma investment in Series C - Keros Therapeutics

foresite-capital_image

Foresite Capital

Foresite Capital investment in Series C - Keros Therapeutics

pontifax_image

Pontifax

Pontifax investment in Series C - Keros Therapeutics

partners-innovation-fund_image

Partners Innovation Fund

Partners Innovation Fund investment in Series C - Keros Therapeutics

cowen-healthcare-investments_image

Cowen Healthcare Investments

Cowen Healthcare Investments investment in Series C - Keros Therapeutics

arkin-bio-ventures_image

Arkin Bio Ventures

Arkin Bio Ventures investment in Series C - Keros Therapeutics

global-health-sciences-venture-fund_image

Global health sciences venture fund

Global health sciences venture fund investment in Series C - Keros Therapeutics

medison-pharma_image

Medison Pharma

Medison Pharma investment in Series B - Keros Therapeutics

Key Employee Changes

Date New article
2022-01-31 Keros Therapeutics Appoints Christopher Rovaldi as Chief Operating Officer

Official Site Inspections

http://www.kerostx.com Semrush global rank: 1.05 M Semrush visits lastest month: 31.93 K

  • Host name: 120.0.153.160.host.secureserver.net
  • IP address: 160.153.0.120
  • Location: Scottsdale United States
  • Latitude: 33.6013
  • Longitude: -111.8867
  • Metro Code: 753
  • Timezone: America/Phoenix
  • Postal: 85260

Loading ...

More informations about "Keros Therapeutics"

Investors & Media - Keros Therapeutics

Jun 6, 2025 The Investor Relations website contains information about Keros Therapeutics's business for stockholders, potential investors, and financial analysts.See details»

Keros Therapeutics - LinkedIn

Keros Therapeutics Biotechnology Research Lexington, Massachusetts 7,270 followers Keros is dedicated to the discovery and development of novel therapeutics for multiple disorders.See details»

Keros Therapeutics - Crunchbase Company Profile

Keros is a clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of novel treatments.See details»

Keros Therapeutics, Inc. (KROS) - Yahoo Finance

See the company profile for Keros Therapeutics, Inc. (KROS) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»

Keros Therapeutics (KROS) Company Profile & Description

Apr 8, 2020 Company profile for Keros Therapeutics, Inc. (KROS) stock, with a description, list of executives, contact details and other key facts.See details»

Overview, News & Similar companies - ZoomInfo.com

View Keros Therapeutics (www.kerostx.com) location in Massachusetts, United States , revenue, industry and description. Find related and similar companies as well as employees by title and …See details»

Keros Therapeutics - businessabc

Jul 21, 2025 Keros was founded in the fall of 2015 with the mission of making novel, life changing therapies for serious and rare diseases with unmet needs. The company was formed …See details»

Keros Therapeutics Company Overview, Contact Details

Jan 3, 2024 Learn more about Keros Therapeutics's company details, contact information, competitors, and more. Find accurate contact data easily with LeadIQ. Book a demo today.See details»

Keros Therapeutics Reports Recent Business Highlights and Fourth ...

Feb 26, 2025 The increase was primarily due to an increase in personnel expenses to support the Company's organizational growth and achievement of its corporate goals, an increase in …See details»

Keros Therapeutics Announces TROPOS Topline Data and …

May 29, 2025 The Company shared top-line results in a presentation that will be accessible in the Investors section of the Keros website at https://ir.kerostx.com. The Company plans to …See details»

Keros Therapeutics CEO and Key Executive Team - Craft.co

Keros Therapeutics's CEO and Director is Jasbir Seehra. Other executives include Christopher Rovaldi, Chief Operating Officer; Keith Regnante, Chief Financial Officer and 7 others. See the …See details»

Corporate Presentation - Keros Therapeutics

These and other risks are described more fully in Keros’ filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Quarterly Report …See details»

Keros Therapeutics Announces Review of Strategic Alternatives

Apr 10, 2025 Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process LEXINGTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. …See details»

SEC Filing - Keros Therapeutics - ir.kerostx.com

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1 (e), …See details»

Keros Therapeutics, Inc. (KROS) - Yahoo Finance

Find the latest Keros Therapeutics, Inc. (KROS) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»

Keros Therapeutics Announces Global License Agreement with …

Dec 3, 2024 Keros Therapeutics to receive upfront payment of $200 million and is eligible to receive development, approval and commercial milestone payments with the potential to …See details»

Keros Reinforces Commitment to Maximizing Stockholder Value

May 8, 2025 Responds to Recent Public Stockholder Communications Urges Stockholders to Protect Their Investment by Voting “FOR” the Company’s Highly Qualified Director Nominees …See details»

SEC Filing - Keros Therapeutics - ir.kerostx.com

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO …See details»

Keros Therapeutics Highlights Commitment to Maximizing …

May 19, 2025 Files Investor Presentation and Issues Open Letter to Stockholders Urges Stockholders to Protect the Value of Their Investment by Voting “FOR” Each of the Company’s …See details»

Keros to Exclusively Prioritize the Clinical Advancement of KER-065

2 days ago Keros also today announced several Board of Directors (the “Board”) and leadership transitions intended to support the Company’s streamlined vision and operational focus. These …See details»

linkstock.net © 2022. All rights reserved